SCHEMBL678787

SCHEMBL678787

CCCCC([C]=O)N1CCCC1

nearest known ligand 0.37

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.37
SLC6A3 Q01959 11/20 0.35
SLC6A2 P23975 8/20 0.35
MAPT P10636 2/20 0.34
ALDH1A1 P00352 1/20 0.34
L3MBTL1 Q9Y468 3/20 0.33
MAPK1 P28482 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
SLC6A4 P31645 5/20 0.32
SIGMAR1 Q99720 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8904036 0.98 HRH3 (0.40) HRH3SLC6A3SLC6A2MAPTALDH1A1
SCHEMBL7290184 0.92 MAPT (0.36) SLC6A3SLC6A2MAPTL3MBTL1MAPK1
SCHEMBL678969 0.88 SLC6A3 (0.38) SLC6A3SLC6A2SLC6A4
SCHEMBL9661910 0.83 SIGMAR1 (0.43) SLC6A2SLC6A4SIGMAR1
SCHEMBL678404 0.79 SLC6A2 (0.30) SLC6A3SLC6A2SLC6A4
SCHEMBL9660844 0.78 SIGMAR1 (0.40) SLC6A2MAPTSLC6A4SIGMAR1
SCHEMBL7427732 0.77 FDPS (0.32) MAPTALDH1A1
SCHEMBL9660265 0.77 GNAO1 (0.40) MAPTSIGMAR1
SCHEMBL9660732 0.77 GNAO1 (0.40) MAPTSIGMAR1
SCHEMBL9661103 0.77 GNAO1 (0.40) MAPTSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170096391-A1 NOVEL LACTAMS BIOSIGNAL LIMITED (AU) 2017-04-06 US disclosed
US-9586901-B2 Lactams UNILEVER PLC (GB) 2017-03-07 US disclosed
US-8586618-B2 Furanone compounds and lactam analogues thereof BIOSIGNAL LIMITED (AU) 2013-11-19 US disclosed
EP-2177226-B1 Hydroxamate compositions COVIDIEN LP (US) 2013-09-18 EP disclosed
US-20130190377-A1 Novel Lactams BIOSIGNAL LIMITED (AU) 2013-07-25 US disclosed
US-8425972-B2 Antimicrobial materials and coatings COVIDIEN LP (US) 2013-04-23 US disclosed
EP-2564859-A1 Hydroxamate compositions Covidien LP (US) 2013-03-06 EP disclosed
US-8153741-B2 Furanone copolymers TYCO HEALTHCARE GROUP LP (US) 2012-04-10 US disclosed
US-8071691-B2 Furanone endcapped polymers TYCO HEALTHCARE GROUP LP (US) 2011-12-06 US disclosed
US-20110280824-A1 Furanone Copolymers TYCO HEALTHCARE GROUP LP (US) 2011-11-17 US disclosed
WO-2001076594-A1 ANTIMICROBIAL COATINGS UNISEARCH LIMITED (AU) 2001-10-18 WO disclosed
WO-2001068090-A1 MICROBIAL INHIBITORY COMPOSITIONS UNISEARCH LIMITED (AU) 2001-09-20 WO disclosed
US-20010020079-A1 Electrophoresis gels and cross-linking agents for their preparation THE UNIVERSITY OF MELBOURNE 2001-09-06 US disclosed
WO-2001043739-A1 INHIBITION OF TWO-COMPONENT SIGNAL TRANSDUCTION SYSTEMS UNISEARCH LIMITED (AU) 2001-06-21 WO disclosed
US-6197906-B1 ASSYMETRIC AGENTS SUCH AS (2-METHACRYLOYLOXYETHYL)ACRYLAMIDE, (2-ACRYLOYLOXYETHYL)METHACRYLAMIDE, AND (N-METHYL-N-ACRYLOYLAMINO)ETHYL METHACRYLATE THE UNIVERSITY OF MELBOURNE (AU) 2001-03-06 US disclosed
WO-2000056792-A1 POLYMER GELS, METHODS FOR THEIR PREPARATION AND THEIR USE IN ELECTROPHORETIC APPLICATIONS THE UNIVERSITY OF MELBOURNE (AU) 2000-09-28 WO disclosed
EP-0920412-A4 ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION UNIV MELBOURNE (AU) 2000-08-02 EP disclosed
EP-0920412-A1 ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION THE UNIVERSITY OF MELBOURNE (AU) 1999-06-09 EP disclosed
WO-1998001419-A1 ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION THE UNIVERSITY OF MELBOURNE (AU) 1998-01-15 WO disclosed
EP-0382185-A2 Carbostyril derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1990-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130190377-A1 Novel Lactams SULT1E1, PGLS, Q6ZSR9 HRH3 3268/4885SLC6A3 4395/4885SLC6A2 4441/4885
US-20110280824-A1 Furanone Copolymers PLA2G5, PLA2G2A, PLA2G10 HRH3 4316/4885SLC6A3 4666/4885SLC6A2 4682/4885
US-20170096391-A1 NOVEL LACTAMS SULT1E1, PGLS, Q6ZSR9 HRH3 3268/4885SLC6A3 4395/4885SLC6A2 4441/4885
US-20010020079-A1 Electrophoresis gels and cross-linking agents for their preparation MACF1, ZYX, F12 HRH3 3281/4885SLC6A3 4884/4885SLC6A2 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.